Generic Name and Formulations:
Probenecid 500mg; scored tabs.
Various generic manufacturers
Indications for Probenecid:
Hyperuricemia associated with gout and gouty arthritis.
250mg twice daily for 1 week, then 500mg twice daily thereafter. Renal impairment, dose adjustments: see literature.
Acute gouty attack. Blood dyscrasias. Uric acid kidney stones. Children <2 yrs of age. Concomitant salicylates (antagonizes uricosuric effect).
History of peptic ulcer. Renal insufficiency. G6PD deficiency. Maintain adequate hydration. Alkalization of urine may be required. Pregnancy.
Affects renal clearance of many drugs (esp. penicillins). Potentiates methotrexate (monitor and reduce methotrexate dose). May potentiate thiopental, ketamine, NSAIDs, oral sulfonylureas, acetaminophen, lorazepam, rifampin, other sulfonamides. Pyrazinamide antagonizes uricosuric effect. May cause falsely high readings of theophylline levels.
Headache, dizziness, GI upset, urinary frequency, sore gums, uric acid kidney stones, dermatitis, fever, hematuria, renal colic, blood dyscrasias, hemolytic anemia; rare: severe allergic reactions, anaphylaxis.
Formerly known under the brand name Benemid.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy